Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.[1]

Its development was terminated on November 08, 1999.[2]

Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production. It's an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), a transcription factor. Darglitazone can increase the effectiveness of insulin in people with obesity and type 2 diabetes. Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production.

Synthesis

Synthesis of darglitazone







References

  1. ↑ Hulin B, Clark DA, Goldstein SW, McDermott RE, Dambek PJ, Kappeler WH, et al. (May 1992). "Novel thiazolidine-2,4-diones as potent euglycemic agents". Journal of Medicinal Chemistry. 35 (10): 1853–64. doi:10.1021/jm00088a022. PMID 1588563.
  2. ↑ "Drug Profile: Darglitazone". Adis Insight. Springer Nature Switzerland AG. Retrieved 28 November 2015.
source: https://en.wikipedia.org/wiki/Darglitazone